Journal
DRUG RESISTANCE UPDATES
Volume 3, Issue 5, Pages 283-287Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1054/drup.2000.0157
Keywords
-
Categories
Funding
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028398] Funding Source: NIH RePORTER
- NIAID NIH HHS [R01 AI028398] Funding Source: Medline
Ask authors/readers for more resources
Atovaquone is a broad-spectrum antiparasitic agent active against malaria, Pneumocystis carinii pneumonia, toxoplasmosis and babesiosis. When used as a single agent, resistance to atovaquone arose rapidly in falciparum malaria, requiring the development of a new antimalarial drug combination of atovaquone and proguanil. Recent laboratory investigations have provided insights into the mode of atovaquone action, and identified the molecular basis for the resistance development. Mutations within a catalytic domain of the cytochrome be, complex present within the parasite mitochondrial inner membrane were shown to be responsible for atovaquone resistance. Here, we review these studies and propose a mechanism by which atovaquone resistance may arise quickly in malaria parasites. (C) 2000 Harcourt Publishers Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available